文献速递神经肿瘤

造釉细胞型颅咽管瘤:美国多中心登记队列(RAPID联盟)结局

Adamantinomatous craniopharyngioma: outcomes from a US multicenter registry cohort (RAPID consortium study).
PubMed 文献 · J Neurosurg · 2026-05-01

基于RAPID联盟的多中心回顾性队列纳入359例组织学确诊的造釉细胞型颅咽管瘤患者,总结手术方式、切除程度、内分泌与放疗结局。全切除仅45%,术后永久性甲状腺功能减退40%、肾上腺功能不全33%。全切除与无进展生存改善独立相关,术后内分泌病高发提示需多学科长期随访。

要点

  • 全切除率45%,全切除与更好PFS独立相关
  • 术后永久性甲减40%、肾上腺功能不全33%
  • PFS由1年66%降至6年31%

核心结论

  • 全切除在不足半数患者中实现,且与无进展生存改善独立相关,切除程度具有预后价值。
  • 术后内分泌病高发,需个体化多学科长期管理。

研究设计与样本

  • RAPID联盟多中心回顾性队列研究,纳入2000年8月至2024年11月在美国高容量垂体中心接受手术、组织学确诊的ACP患者。
  • 共359例(男性206例,初次手术中位年龄47岁)。

主要发现

  • 76%行内镜经蝶手术,22%行开颅手术。
  • 全切除45%,次全切除47%。
  • 311例中120例(39%)术前存在下丘脑-垂体轴功能障碍。
  • 治疗后永久性甲状腺功能减退40%、肾上腺功能不全33%、精氨酸加压素缺乏19%。
  • 263例初次手术患者中84例(32%)接受放疗;PFS由1年66%降至6年31%。

关键数值与推荐

  • 多因素分析中更差PFS的独立预测因素:次全切除(HR 0.22,95%CI 0.11-0.42;p=0.001)、部分切除(HR 0.11,95%CI 0.04-0.28,p=0.001)、肿瘤体积较大(HR 0.77,95%CI 0.64-0.94;p=0.009)、肿瘤超出鞍区与鞍上区(HR 0.21,95%CI 0.06-0.74;p=0.016)。
  • 初次手术组与挽救手术组PFS相当。

临床怎么用

  • 术前应评估下丘脑-垂体轴功能,术后预期并监测永久性甲减、肾上腺功能不全及精氨酸加压素缺乏。
  • 对未能全切除者应结合放疗等多学科方案并加强长期随访。

局限性

  • 回顾性设计;结果来自美国高容量垂体中心,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Adamantinomatous craniopharyngioma (ACP) is a rare type of brain tumor that affects a wide age range, from children to older adults. Due to the rarity of the disease, existing studies are predominantly limited to single-center or single-surgeon experiences, often lacking statistical power and generalizability. The aim of this study was to address this gap by providing a comprehensive analysis of ACP outcomes based on a large multicenter cohort from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID). METHODS: This multicenter retrospective cohort study was conducted via the RAPID consortium and assessed patients with histologically confirmed ACP treated surgically between August 2000 and November 2024 at high-volume pituitary centers across the United States. RESULTS: Among the 359 patients (206 male, median age at primary surgery of 47 years) included in the analysis, 76% underwent endoscopic transsphenoidal surgery and 22% underwent craniotomy. Gross-total resection was achieved in 45% and subtotal resection in 47%. Notably, 120 of 311 patients (39%) presented with preoperative hypothalamic-pituitary axis dysfunction. Following all treatments, permanent hypothyroidism was reported in 40% of patients, adrenal insufficiency in 33%, and arginine vasopressin deficiency in 19%. Of 263 patients who underwent primary surgery, radiation therapy was administered in 84 (32%). Progression-free survival (PFS) declined from 66% at 1 year to 31% at 6 years. In the multivariable analysis, independent predictors of worse PFS included subtotal resection (HR 0.22, 95% CI 0.11-0.42; p = 0.001), partial resection (HR 0.11, 95% CI 0.04-0.28, p = 0.001), larger tumor size (HR 0.77, 95% CI 0.64-0.94; p = 0.009), and tumor extension beyond the sella and suprasellar regions (HR 0.21, 95% CI 0.06-0.74; p = 0.016). Primary surgery and salvage surgery groups showed comparable PFS. CONCLUSIONS: In this large multicenter cohort study, gross-total resection was achieved in fewer than half of patients and was independently associated with improved PFS. Approximately one-third of patients underwent radiation therapy after primary surgery. These findings provide robust evidence supporting the prognostic value of extent of resection and inform contemporary treatment algorithms for ACP. The high incidence of postoperative endocrinopathy underscores the need for individualized multidisciplinary long-term care. While the retrospective design is a limitation, the multicenter approach enhances the generalizability of these results.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Shinya Y, Palit SR, Peris Celda M, et al. Adamantinomatous craniopharyngioma: outcomes from a US multicenter registry cohort (RAPID consortium study). J Neurosurg. 2026. PMID: 42066361. doi:10.3171/2025.12.JNS252065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。